Reuters logo
UPDATE 1-Pluristem prices public offering of 8 mln units at $4/shr
September 13, 2012 / 2:30 PM / 5 years ago

UPDATE 1-Pluristem prices public offering of 8 mln units at $4/shr

JERUSALEM, Sept 13 (Reuters) - Israel-based Pluristem Therapeutics Inc seeks to raise about $32 million from a planned public offering of stock and warrants next week.

Pluristem said on Thursday it has priced 8 million units consisting of one share of the company’s stock and one warrant to purchase 0.35 of a share at $4 each. The offering is expected to close on or about Sept. 19, it said.

Each warrant will be exercisable for a period of five years at an exercise price of $5.00. The company has also granted the underwriters a 30-day option to purchase up to 1.2 million shares of common stock and/or warrants to purchase up to 420,000 shares of common stock to cover over-allotments, if any.

Jefferies & Co is the book-running manager for the offering, with Oppenheimer & Co as co-lead. Needham & Co and Maxim Group are co-managers, while Leader Capital Markets is acting as a financial advisor to the company.

Last month, Pluristem said a second patient suffering from bone marrow failure was saved using its placenta-based stem cell treatment.

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below